Pays: Irlande
Langue: anglais
Source: HPRA (Health Products Regulatory Authority)
PRAZIQUANTEL, PYRANTEL EMBONATE
Bayer Limited
QP52AA51
PRAZIQUANTEL, PYRANTEL EMBONATE
Unknown
Tablets
CAM-Companion Animal Medicine
Feline
Praziquantel, combinations
Endoparasiticide
Authorised
1995-09-22
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Drontal Cat Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Tablet White to yellowish scored coated tablet. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of gastrointestinal roundworms and tapeworms: _Toxocara cati, Toxascaris leonina, Dipylidium caninum, Taenia taeniaeformis._ 4.3 CONTRAINDICATIONS Do not use simultaneously with piperazine compounds. Not intended for use in kittens less than 6 weeks of age. Do not use during pregnancy. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Fleas serve as intermediate hosts for one common type of tapeworm-_Dipylidium caninum_. Tapeworm infestation is certain to re-occur unless control of intermediate hosts such as fleas, mice etc is undertaken. As a precautionary measure to prevent establishment of_ Echinococcus multilocularis_ in the UK and Ireland, it is recommended that all dogs and cats entering the country be treated with praziquantel. 2.1 ACTIVE CONSTITUENTS MG PER TABLET Pyrantel Embonate 230.0 Praziquantel 20.0 2.2 RELEVANT CONSTITUENTS OF THE EXCIPIENTS Titanium Dioxide E171 1.8 H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _2_ _8_ _/_ _0_ _4_ _/_ _2_ _0_ _1_ _7_ _C_ _R_ _N_ _ _ _7_ _0_ _2_ _6_ _6_ _2_ _4_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ 4.5 Lire le document complet